Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 549

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1C
Chunk 549
---
 Center. He has served as the protocol chair for RTOG clinical trials that
advanced the use of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional
5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and
book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and
completed residencies in internal medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General Hospital,
Harvard Medical School.

Milton
Brown, M.D., Ph.D., FNAI. Dr. Brown is a co-founder of our Company, previously served as our Chief Scientific Officer for Chemistry,
and has served a member of our Board of Directors since the Company’s formation in December 2012. Since August 2022, Dr. Brown
has also served as Vice Dean of Research, Professor of Internal Medicine and the Prudence and Louis Ryan endowed chair in translational
research at Eastern Virginia Medical School. Previously, he was Director of the Center for Drug Discovery at the George Mason University
from 2020 to 2022 and Director of the Inova Center for Drug Discovery and Development from 2016 to 2020. Dr. Brown was a founder of Rivanna
Pharmaceuticals in 2004 and co-founder, Chairman and Chief Executive Officer of Trocar Pharma
in 2020, both of which are Virginia-based biopharmaceutical companies engaged in the discovery and development of novel small molecule
therapeutics for the treatment of neurological, oncological, and infectious diseases. Dr. Brown has also served as Director of the Drug
Discovery Center at Georgetown University Medical School from 2012 to 2016 and principal investigator of the NIH/NCI funded Chemical
Diversity Center from 2010 to 2015. Dr. Brown brings to Shuttle Pharma 25 years of experience in drug discovery with over 100 publications
and 67 issued patents, including discovery of novel HDAC inhibitors. Dr. Brown was a 2015 recipient of the Percy Julian Award by the
National Organization of Black Chemists and Chemical Engineers for significant contributions in pure and/or applied research in science.
He has served on government committees including the NIH Experimental Therapeutics Study Section, the NIH Drug Discovery and Molecular
Pharmacology Study Section and was a scientific counselor to the U.S. Secretary of Health